AstraZeneca hints restructuring may trim R&D budget and move trials to emerging markets

AstraZeneca's chief executive Pascal Soriot told journalists that the company's new restructuring program could lead to cost reductions in research and development and may see some clinical trials relocated to emerging markets.

The changes are being considered as the firm prepares for the loss of patent protection on products such as Farxiga, and aim to cut expenses and reduce staff numbers.

Shifting trials abroad could affect study timelines and collaborations, and market observers see the plan as an indication of financial pressure on the drugmaker.